AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
The medicine was well tolerated, with no unexpected safety issue
The medicine was well tolerated, with no unexpected safety issue
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Guidelines aim to establish state-regulated veterinary blood banks
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Subscribe To Our Newsletter & Stay Updated